Featured Stories
Biosimilar Infliximab Success Paves The Way For Adalimumab In Europe
With the impending European launch of Humira biosimilar adalimumab in October, Scrip talks to some of those in the region that have experience in launching commercially successful biosimilars about uptake, discounts and payer attitudes.
In Conversation With Novo Nordisk CMO: The Ongoing Fight Against Diabetes
Stephen Gough has kept his connections with Oxford University and will see collaborations between the two expand next month with the opening of the Novo Nordisk Research Centre Oxford. The executive spoke to Scrip.
Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain
The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.
Latest News
Recent Tweets from ScripAccelerating Cancer Drug Development
Attrition rates in drug discovery and development have been a major bane to the pharmaceutical industry and contribute greatly to the high cost of research and development. These challenges are magnified in oncology. Click the link below and discover how SMEs are delivering oncology breakthroughs and improving preclinical insights.
Formulation In The Drug Product Development Process
Rentschler Biopharma, Leukocare Biotechnology and Pharma Intelligence are undertaking a brief survey to gather insight into the importance, expectations and common challenges of drug product formulation. Each respondent to complete the survey will get a chance to win one of four $50 Visa gift cards.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Deal Watch, Licensing Focus: Roche, Sanofi Exit Ongoing Anticalin Development Efforts With Pieris
Sarepta licenses gene therapy candidate from Lacerta, also makes equity investment. Neuren licenses North American rights to rare disease drug trofinetide to Acadia.
Interview: BioNTech And Pfizer Explore mRNA Flu Vaccines In $120m+ Deal
The German biotech's CBO and CCO Sean Marett tells Scrip that the Pfizer pact represents the first time BioNTech has moved into infectious disease in humans and could lead to higher potency flu vaccines that could be made more rapidly and cheaply.
CVS Sees Growing Physician, Patient Use Of Real-Time Drug Price Data
Prescribers are reviewing patient benefits information nearly 280,000 times per week while patients are using an online Check Drug Cost tool 250,000 times per month – and the numbers are growing.
Enthusiasm For US Biosimilars Wanes For Some, But Not Others
Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.
Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows
The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.
It's No Cosentyx/Taltz But Ilumya Pleases Customers, Says Sun
Sun Pharma acknowledged the intense competition that awaits its psoriasis asset, Ilumya (tildrakizumab) in the US, but maintained that the overall profile of the IL-23p19 inhibitor, which is expected to debut in Q2FY19, was “liked” by customers.
Private Longeveron Bets On Stem Cells For Inflammation, Aging Diseases
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
Deal Watch, Focus On Acquisitions: Emergent Acquires PaxVax, Pair Of Commercialized Vaccines
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
How Big A Blow To Biogen Is NICE 'No' For Spinraza?
The US biotech is aghast that the cost-effectiveness committee for England, Wales and Northern Ireland is minded to reject its effective but pricey SMA therapy which has gained blockbuster status already on strong sales elsewhere in Europe and the US.
Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay
Insmed’s Amikacin Moves Closer To US Market In Refractory Lung Disease
FDA panel's recommendation that liposome inhalation suspension be labeled only for refractory nontuberculous mycobacterial lung disease and not first-line use aligns with analyst expectations; panel cites lack of clinical studies in treatment-naive patients and adverse event profile as reasons for limiting drug to patients with limited or no treatment options.
Express Scripts Rewards Low List-Priced Brands In 2019 Formulary, Retains Focus On Rebates
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
ViiV/Janssen's Long-Acting Anti-HIV Injections Impress
A dual regimen consisting of long-acting injectable formulations of the integrase inhibitor cabotegravir and the nnRTI rilpivirine was as effective as the oral standard-of-care regimen of three drugs daily, in interim results from the ATLAS study.
Bayer Targets COPD In Haplogen Antiviral Pact
Respiratory viral infections are a frequent cause of COPD exacerbations and the German major is joining forces with the Austrian biotech and Evotec to find new antivirals to tackle the disease.
Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay
Gemphire Reels From Two R&D Blows
A series of setbacks for gemcabene has left the Livonia, MI-based company reeling, but management remains committed to its lead product.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.